Tenapanor

Phase 3Recruiting

2 views this week 0 watching⚡ Active💊Featured in Rare Disease Pipeline Watch

Interest: 41/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cystic Fibrosis

Conditions

Cystic Fibrosis, Constipation

Trial Timeline

Jun 1, 2025 → Jun 30, 2027

NCT ID

NCT06810167

About Tenapanor

Tenapanor is a phase 3 stage product being developed by Ardelyx for Cystic Fibrosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06810167. Target conditions include Cystic Fibrosis, Constipation.

What happened to similar drugs?

20 of 20 similar drugs in Cystic Fibrosis were approved

Approved (20) Terminated (7) Active (0)

✅CefiderocolShionogiApproved

✅CREONAbbVieApproved

✅Pancrelipase + PancrelipaseAbbVieApproved

✅Tedizolid PO + Tedizolid IVMerckApproved

✅Alendronate + PlaceboMerckApproved

✅tredaptive (nicotinic acid/ laropiprant) + placeboMerckApproved

✅Ceftolozane/TazobactamMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06810167	Phase 3	Recruiting	Jun 1, 2025	Jun 30, 2027	Cystic Fibrosis
NCT05995899	Approved	Completed	Feb 6, 2024	Dec 17, 2025	IBS
NCT06203444	Phase 1	Completed	Nov 27, 2023	May 30, 2024	Lactation
NCT05905926	Phase 3	Recruiting	Feb 17, 2023	Oct 1, 2031	Irritable Bowel Syndrome With Constipation (IBS-C)
NCT04549597	Approved	Completed	Nov 20, 2020	Dec 1, 2021	Chronic Kidney Disease Requiring Chronic Dialysis
NCT02727751	Phase 3	Completed	Mar 1, 2016	Oct 1, 2017	Constipation Predominant Irritable Bowel Syndrome

Competing Products

20 competing products in Cystic Fibrosis

See all competitors

Product	Company	Stage	Hype Score
VX-522 mRNA therapy + IVA	Moderna	Phase 1/2	36
Tildacerfont + Placebo	Spruce Biosciences	Phase 2	17
Enfortumab Vedotin	Astellas Pharma	Phase 2	42
Cefiderocol	Shionogi	Approved	43
Lenvatinib	Eisai	Phase 2	39
Lenvatinib + Pembrolizumab	Eisai	Phase 2	39
CREON	AbbVie	Approved	43
Pancrelipase + Pancrelipase	AbbVie	Approved	43
Creon IR + Creon® (DR/GR)	AbbVie	Phase 2	35
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
Elagolix + Placebo	AbbVie	Phase 2	35
ABBV-3067 + Placebo ABBV-3067 + ABBV-2222 + Placebo ABBV-2222	AbbVie	Phase 2	35
ABBV-576 + Galicaftor + Placebo + Navocaftor + ABBV-119	AbbVie	Phase 2	27
Benralizumab + Placebo to Benralizumab	AstraZeneca	Phase 3	32
AZD5634 for inhalation + AZD5634 for infusion	AstraZeneca	Phase 1	29
Metformin XR + Saxagliptin + Saxagliptin-Metformin XR	AstraZeneca	Phase 3	40
AZD1236 + Placebo	AstraZeneca	Phase 2	27
Exenatide once weekly (EQW ) + Dapagliflozin (DAPA) + EQW plus DAPA + Dapagliflozin plus Glucophage (MET ER) + Phentermine /Topiramate (PHEN/ TPM) ER	AstraZeneca	Phase 3	40
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
AZD9668 + AZD9668 Placebo equivalent	AstraZeneca	Phase 2	35